Asparaginase Erwinia chrysanthemi Clinical Trials
6 recruitingDrug
Phase 24Phase 31Phase 11
Showing 1–6 of 6 trials
Recruiting
Phase 2
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Acute Leukemia of Ambiguous LineageB Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)153 enrolled108 locationsNCT06317662
Recruiting
Phase 2
Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeT Acute Lymphoblastic Leukemia
University of Washington30 enrolled1 locationNCT06738368
Recruiting
Phase 1
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
City of Hope Medical Center26 enrolled1 locationNCT07133997
Recruiting
Phase 2
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Lymphoblastic LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
City of Hope Medical Center53 enrolled8 locationsNCT06918431
Recruiting
Phase 2
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic Lymphoma+1 more
Children's Oncology Group80 enrolled157 locationsNCT02981628
Recruiting
Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Acute Myeloid Leukemia
Children's Oncology Group1,186 enrolled205 locationsNCT04293562